Related Articles
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
Survival analysis with regard to PD‑L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors
The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials
Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers